Supplementary Table 1, Supplementary Table 2A, Supplementary Table 2B, Supplementary Table 3, Supplementary Table 4, or Supplementary Table 5 from <i>TWIST1</i> Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy

Supplementary Table 1. Summary of EMT-related SNPs Supplementary Table 2A. Association between baseline characteristics and clinical outcomes in the bevacizumab cohort Supplementary Table 2B. Association between baseline characteristics and clinical outcomes in the cetuximab cohort Supplementary Table 3. Association between TWIST1 rs2285682 and clinical outcomes in KRAS wild-type and mutant subgroups among the bevacizumab cohort Supplementary Table 4. Association between EMT-related SNPs and clinical outcomes stratified by gender in the bevacizumab cohort Supplementary Table 5. Association between TWIST1 rs2285682 and clinical outcomes in the cetuximab cohort